Home > Healthcare > Medical Devices > Therapeutic Devices > Topical Wound Agents Market

Topical Wound Agents Market Share

Report ID: GMI7712
Published Date: Dec 2023
Report Format: PDF

Download Free Sample

Topical Wound Agents Market Share

The topical wound agents industry is consolidated, with key players including Smith & Nephew Plc., Teva Pharmaceutical Industries Ltd, Mylan N.V., AstraZeneca, and others dominating the market. These companies focus on ongoing product innovation, geographical expansion, and partnerships to secure substantial position in the market. For instance, in February 2023, SERDA Therapeutics, a biopharmaceutical company, announced the submission of an Investigational New Drug Application (IND) to the U.S. FDA for its flagship product, SN514 hydrogel. SN514 hydrogel is a groundbreaking enzymatic wound debriding agent developed by the company. This move substantially broadened company’s array of products, leading to increased revenue streams for the company.

Topical Wound Agents Market Companies

Some of the eminent market participants operating in the topical wound agents industry include:

Smith & Nephew plc
Teva Pharmaceutical Industries Ltd.
Mölnlycke Health Care AB
Arch Therapeutics, Inc.
Mylan N.V.
AstraZeneca
Osiris Therapeutics, Inc.
3M Company
Coloplast A/S
Medline Industries, Inc.
B. Braun Melsungen AG
Integra LifeSciences Corporation
Paul Hartmann AG
SERDA Therapeutics
Bausch Health Companies Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for topical wound agents was valued at USD 1.7 billion in 2023 and is estimated to reach USD 3.4 billion by 2032, owing to the rising prevalence of both chronic and acute wounds.

The chronic wound segment accounted for 79% market share in 2023, driven by the need to address specific challenges associated with diabetic ulcers, reduce complications, and promote effective wound healing in individuals with diabetes.

U.S. market accounted for USD 710 million revenue size in 2023, backed by aging population in the region, having slow wound healing and skin issues, creating a higher demand for wound care solutions.

Smith & Nephew plc., Teva Pharmaceutical Industries Ltd., Mölnlycke Health Care AB, 3M Company, Medline Industries, Inc., Arch Therapeutics, Inc. Mylan N.V., AstraZeneca and Osiris Therapeutics, Inc.